Diagnamed Holdings Corp. · CSE:DMED
Diagnamed — Investor Presentation (November 2024)
18 slides from Diagnamed's investor presentation, November 2024
Slide 1: DiagnaMed Holdings Corp. Corporate Presentation
DiagnaMed Holdings Corp. Corporate Presentation NOVEMBER 2024 CSE: DMED | OTCQB: DGNMF
Slide 2: Summary
Summary Focused on therapeutics and diagnostics for Brain Health +2 billion people with mental health and neurological disorders HydroPharm™, patent-pending oral molecular hydrogen product BRAIN AGE® AI Brain Health Platform Growing commercial and clinical partnerships Multiple value-creating milest
Slide 3: Brain Health Market
Brain Health Market +1 Billion +1 Billon Mental Health Neurodegenerative DiagnaMed CSE: DMED | OTCQB: DGNMF
Slide 4: Unlocking the medical potential of Hydrogen
Unlocking the medical potential of Hydrogen DiagnaMed CSE: DMED | OTCQB: DGNMF
Slide 5: Molecular Hydrogen
Molecular Hydrogen Molecular hydrogen therapy is a rapidly growing field and poised for clinical adoption Over 2,000 scientific publications on potential therapeutic effects in over 100 human studies Clinically demonstrated to provide antioxidant, anti- inflammatory and neuroprotective effects Diagn
Slide 6: Potential Medical Uses of Hydrogen
Potential Medical Uses of Hydrogen Our Current Focus Brain Dementia Parkinson’s disease Depression Alzheimer’s disease TBI/Concussions Stroke Stroke Aging Ischemia/reperfusion injuries Inflammation Metabolic Syndrome Side effects by cancer drugs Organ Transplants Sepsis Diabetes Radiotherapy Post-ca
Slide 7: Clinical Validation
Clinical Validation DiagnaMed CSE: DMED | OTCQB: DGNMF
Slide 8: Limitations of Molecular Hydrogen
Limitations of Molecular Hydrogen Clinical use is limited primarily due to its: Low hydrogen content Rapid evaporating action in water Lower effective concentration and poor stability Hydrogen inhalation and hydrogen-rich water machines are: Expensive, bulky and complex to use Challenging to determi
Slide 9: Our Solution
Our Solution HydroPharm™ - novel ‘patent-pending’ oral molecular hydrogen tablet tailored for mental health and neurological disorders Offering different doses, durations, and methods of administration HydroPharm™ Hydrogen producing oral tablets License technology that enable natural hydrogen to mee
Slide 10: Utilizing AI for Brain Health
Utilizing AI for Brain Health DiagnaMed CSE: DMED | OTCQB: DGNMF
Slide 11: BRAIN AGE AI: Estimating BRAIN AGE
B R A I N A G E A I ® Estimating BR AIN AGE® Providing Brain Health Risk Score Monitoring Overall Brain Health DiagnaMed CSE: DMED | OTCQB: DGNMF
Slide 12: Clinical Validation
Clinical Validation DiagnaMed CSE: DMED | OTCQB: DGNMF
Slide 13: Features
Features Brain Age Brain Health 1 2 Estimation Risk Score Use of novel EEG Evaluate overall device and ML/AI brain health risk techniques for score, and provide predicting and actionable data. monitoring brain age. BR A IN AGE® 4 Brain Health 3 Brain Health Maintenance Support Ongoing evaluation Use
Slide 14: 2025 Growth Plan
2025 Growth Plan BR A IN AGE® Commercializing HydroPharm™ & BR AIN AGE® AI Molecular Hydrogen Products Unlock new uses of HydroPharm™ & BR AIN AGE® AI Clinical therapeutic and diagnostic tools for screening, monitoring and treating mental health, neurological and brain injuries Establish HydroPharm™
Slide 15: Relationships
Relationships DiagnaMed CSE: DMED | OTCQB: DGNMF
Slide 16: Team
Team Management Research Fabio Chianelli Dr. John Kounios, PhD Founder, Chairman, and CEO Principal Researcher - Brain Age Founder, CEO - PharmaTher Applied Cognitive & Brain Sciences Professor, Founder, President - Revive Thera Drexel University Jing Peng, CPA Dr. James E Galvin, M.D., M.P.H. Chief
Slide 17: Financial Snapshot
Financial Snapshot 80,052,640 2,000,000 Common Shares outstanding Stock Options 37,382,226 Common Shares are subject to escrow 1/10th released at: November 8, 2023, 2024, 2025 ~ 21% May 8, 2024, 2025, 2026 2/10th released at: Insider Ownership November 8, 2026
Slide 18: Thank You
THANK YOU DiagnaMed Holdings Corp. 82 Richmond Street East Toronto, ON M5C 1P1 t. 416-800-2684 e. [email protected] DiagnaMed CSE: DMED | OTCQB: DGNMF
DiagnaMed Holdings — Investor Presentation (November 2024) on 6ix